Pharmacovigilance
February 2026
Managing ICSR Backlogs: Why Small Pharma Companies Lose Control of Their Safety Databases — and How to Recover
For small and mid-size pharmaceutical companies, Individual Case Safety Report backlogs are one of the most quietly dangerous compliance risks in the post-marketing phase. Unlike a failed regulatory submission — which generates immediate, visible consequences — a growing ICSR backlog can accumulate for months before it becomes a formal inspection finding.
Read article
GCC Regulatory
January 2026
Navigating Multi-Market Registration in the GCC: Why Parallel Submissions Require a Different Operational Model
Companies entering the GCC pharmaceutical market often underestimate the operational demands of running simultaneous submissions across MOHAP, SFDA, and other health authorities. The technical regulatory requirements are well-documented. The operational infrastructure required to execute them efficiently is less discussed.
Read article
Operations
December 2025
The Trial Master File at Inspection: What Regulators Look for and What Operations Teams Miss
The Trial Master File is the documentary evidence that a clinical trial was conducted according to GCP. When inspectors arrive, they assess the TMF for completeness, contemporaneity, and accuracy. Most deficiencies are operational — and preventable.
Read article